Low doses of antigen coupled to anti-CR2 mAbs induce rapid and enduring IgG immune responses in mice and in cynomolgus monkeys

Molecular Immunology
Emily C WhippleMargaret A Lindorfer

Abstract

The complement system and B cell complement receptor 2 (CR2), specific for C component C3dg, play important roles in both the innate and adaptive immune response. We used hapten and protein conjugates of anti-CR2 mAbs as models for C3dg-opsonized antigens and immune complexes to examine the handling of and immune response to these reagents in mice and in non-human primates (NHP). Mice immunized and boosted i.v. with only 100 ng of Alexa 488 rat anti-mouse CR1/2 mAb 7G6 had strong IgG immune responses to the Alexa 488 hapten and to rat IgG, compared to very weak immune responses in mice treated with a comparable isotype control; larger doses of Alexa 488 mAb 7G6 did not increase the immune response. A vaccine constructed by cross-linking anthrax protective antigen to mAb 7G6 proved to be effective at low doses in generating sufficiently high titer serum IgG antibodies to neutralize anthrax lethal toxin in vitro and to protect mice from i.v. challenge with anthrax lethal toxin. When biotinylated HB135, a mouse mAb specific for human CR2, was injected i.v. into NHP, the probe manifested the same initial marginal zone B cell binding and subsequent localization to follicular dendritic cells as we have previously reported for compara...Continue Reading

References

Aug 1, 1990·The Journal of Experimental Medicine·B HeymanT Kinoshita
Jan 1, 1984·European Journal of Immunology·D GrayH Bazin
Apr 1, 1996·The Journal of Experimental Medicine·D A CroixM C Carroll
Jun 3, 2000·Annual Review of Immunology·D T Fearon, M C Carroll
Oct 31, 2001·Journal of Immunological Methods·S E HensonD R Karp
Sep 10, 2003·Proceedings of the National Academy of Sciences of the United States of America·Gi-Eun RhieJulia Y Wang
Jan 27, 2004·Infection and Immunity·Gary R MatyasCarl R Alving
Jul 24, 2004·The Journal of Infectious Diseases·Richard T KenneyGregory M Glenn
Aug 25, 2004·International Immunology·Andrew R FergusonRonald B Corley
Sep 3, 2004·Proceedings of the National Academy of Sciences of the United States of America·G HermansonP Hobart
Sep 30, 2004·Nature Immunology·Michael C Carroll
Nov 3, 2004·Vaccine·Donald J ChabotArthur M Friedlander
Dec 21, 2004·The Journal of Infectious Diseases·John A MiksztaNoel G Harvey

❮ Previous
Next ❯

Citations

Dec 5, 2009·Nature Reviews. Drug Discovery·Eric Wagner, Michael M Frank
Oct 20, 2009·Vaccine·Arthur M Friedlander, Stephen F Little
Jan 5, 2011·Immunological Reviews·Theodor ChitlaruAvigdor Shafferman
Aug 16, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Paul V BeumRonald P Taylor
Sep 6, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Yongli LiRonald P Taylor
Oct 4, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Andrew W PawluczkowyczRonald P Taylor
May 5, 2017·JCI Insight·Jeffrey L PlattMarilia Cascalho

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.